Pyrazolo[1,5-A]pyridine compounds and use thereof
US10155756B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 13, 2015 |
| Grant date | Dec 18, 2018 |
| Priority date | — |
| Expiry date | Aug 13, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed in the disclosure are a pyrazolo [1,5-a] pyrideine compound with structural features as shown in formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (MIC) of the compounds is lower than 0.1 μg/mL and partially achieves 0.01 μg/mL, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (MDR-TB) strains. In an in vivo experiment, the pyrazolo[1,5-a] pyrideine compounds of the present disclosure can effectively scavenge the infectious dose of H37Ra in a mouse body at 20 mg/kg/d does, thereby being a new type of antituberculosis compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.